Home Stock

Stock Research: UCB

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

UCB

BRU:UCB BE0003739530
22
  • Value
    32
  • Growth
    72
  • Safety
    Safety
    49
  • Combined
    45
  • Sentiment
    23
  • 360° View
    360° View
    22
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

UCB SA is a biopharmaceutical and specialty chemical company specializing in central nervous system (CNS) and immunology diseases. Its main business includes CNS disorders like epilepsy and immunology disorders such as rheumatoid arthritis. UCB SA operates globally, with a focus on Europe and North America. In the last fiscal year, the company had a market cap of $39,605 million, profits of $4,555 million, revenue of $6,369 million, and 9378 employees.

more

ANALYSIS: With an Obermatt 360° View of 22 (better than 22% compared with alternatives), overall professional sentiment and financial characteristics for the stock UCB are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for UCB. The consolidated Growth Rank has a good rank of 72, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 72% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 32 means that the share price of UCB is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 68% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 49, which means that the company has a riskier financing structure than 51% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 23, indicating professional investors are more pessimistic about the stock than for 77% of alternative investment opportunities. ...read more

more
Strongest Rank Market Pulse
Weakest Rank Profit Growth
Country Belgium
Industry Pharmaceuticals
Size Small
Website ucb.com
Index
BEL20
UCB stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
32 6 79 74
Growth
72 90 89 19
Safety
Safety
49 24 24 38
Sentiment
23 61 10 38
360° View
360° View
22 37 45 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
50 49 36 49
Opinions Change
50 59 24 48
Pro Holdings
n/a 45 14 56
Market Pulse
1 69 47 27
Sentiment
23 61 10 38
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
32 6 79 74
Growth
72 90 89 19
Safety Safety
49 24 24 38
Combined
45 24 82 32
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
32 11 46 54
Price vs. Earnings (P/E)
22 15 54 71
Price vs. Book (P/B)
50 21 81 78
Dividend Yield
47 32 70 65
Value
32 6 79 74
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
64 94 54 6
Profit Growth
79 54 77 48
Capital Growth
46 56 76 21
Stock Returns
60 96 52 54
Growth
72 90 89 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
60 61 48 43
Refinancing
21 18 23 24
Liquidity
64 31 40 56
Safety Safety
49 24 24 38

Similar Stocks

Discover high‑ranked alternatives to UCB and broaden your portfolio horizons.

Polski Koncern Naftowy ORLEN Spolka Akcyjna

WSE:PKN
Country: Poland
Industry: Oil & Gas Refining
Size: XX-Large
Full Stock Analysis

Volkswagen VW

GER:VOW
Country: Germany
Industry: Automobile Manufacturers
Size: XX-Large
Full Stock Analysis

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Barco

BRU:BAR
Country: Belgium
Industry: Electronic Equipment
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The only positive is high growth. The stock is expensive (low Value Rank), risky to finance, and carries critical professional sentiment. This is a risky proposition. Avoid unless you have exceptional conviction that the growth alone will overcome the price and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews